House Republican legislation to repeal and replace portions of the Affordable Care Act (ACA) will have a negligible effect on the biopharma industry, Pfizer Inc. Chairman and CEO Ian Read said in a speech at the National Press Club in Washington, DC March 23.
"I don't believe there's any short term impact for the industry," Read commented in response to a question. But "there's...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?